Cowen’s biotech team weighs in with upbeat perspectives on biotech firms Gilead Sciences, Inc. (NASDAQ:GILD), Exelixis Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been awarded the California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™ (pimavanserin), the …
ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) pipeline drug Nuplazid was approved in May to treat Parkinson’s Disease Psychosis (PDP) and launched the following month.
H.C.
Cowen analyst Ritu Baral is out with a positive research note on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after hosting a group meeting last …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central …
JMP Securities analyst Jason Butler weighs in on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after the biotech company reported second-quarter financial results that …
In ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) second-quarter report, investors got a first glimpse of Nuplazid’s early launch in Parkinson’s disease psychosis (PDP).
In a research report issued this morning, Needham analyst Alan Carr weighed in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker released its second-quarter financial …
